Volume 18, Number 5—May 2012
Dispatch
Use of Spatial Information to Predict Multidrug Resistance in Tuberculosis Patients, Peru
Table
Characteristic | Univariate OR† (95% CI) | p value | Multivariate OR† (95% CI)‡ | p value |
---|---|---|---|---|
Age, per 10-y increase | 0.89 (0.81–0.99) | 0.034 | 0.90 (0.81–1.00) | 0.046 |
Male sex | 1.09 (0.81–1.46) | 0.58 | 1.05 (0.78–1.43) | 0.74 |
Negative sputum smear test results | 2.05 (1.37–3.08) | <0.001 | 2.11 (1.40–3.19) | <0.001 |
HIV infection | 0.59 (0.31–1.13) | 0.11 | 0.52 (0.27–1.00) | 0.049 |
History of TB treatment | 2.38 (1.78–3.18) | <0.001 | 2.41 (1.80–3.23) | <0.001 |
Known household contact with persons with MDR TB | 1.18 (0.89–1.57) | 0.25 | 1.08 (0.81–1.44) | 0.59 |
*MDR, multidrug resistant; TB, tuberculosis; DST, drug-susceptibility testing; OR, odds ratio.
†ORs represent risk for MDR TB conditional on receiving DST. For example, even if household contact with persons with MDR TB is marginally associated with increased risk for MDR TB, the observed association would likely be attenuated when the analysis is restricted to those who received DST because household contact with persons with MDR TB is an accepted criterion for ordering DST.
‡Adjusted for all other variables listed.
Page created: April 05, 2012
Page updated: April 12, 2012
Page reviewed: April 12, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.